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Abstract 
Introduction: Several therapeutic approaches have been developed to treat choroidal 
hemangioma. However, all these therapies are associated with a potential risk of 
damaging the overlying retina.  
Case Report: We report a case of circumscribed choroidal hemangioma (CCH) in a 59-
year-old man refractory to laser treatment. Visual acuity was 20/200 and a serous macular 
detachment was present. The CCH was treated with oral propanolol, whereupon visual 
acuity improved to 20/20 and the macular detachment resolved without systemic or 
local adverse effects.  
Discussion: Propanolol is a β-blocker commonly used in cardiology that may induce 
endothelium vasoconstriction and inhibit endothelial proliferation. It has been shown to 
be effective in infantile facial hemangiomas, and proved safe and effective for the CCH in 
our patient. Further studies are needed to confirm our observation. 
Introduction 
There are two types of choroidal hemangiomas: circumscribed choroidal hemangioma 
(CCH) and diffuse choroidal hemangioma (DCH). 
CCH is a rare benign, commonly asymptomatic vascular tumor which is usually 
diagnosed in adulthood when it becomes symptomatic with visual acuity decline, visual 
field defect or metamorphopsia due to exudative retinal detachment. CCH appears as an 
orange choroidal mass with indistinct borders, usually within the macular area [1].  
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In contrast, DCH is usually evident at birth and typically occurs as part of neuro-
oculocutaneous hemangiomatosis (Sturge-Weber syndrome), but it frequently does not 
become manifest until adolescence. DCH appears as a diffuse orange choroidal 
thickening. Despite this, focal regions of excessively thickened choroid may simulate 
CCH [2]. 
Choice of treatment for choroidal hemangiomas is based on tumor location, presence 
of subretinal fluid, extent of symptoms, and potential for visual recovery. Periodic 
observation alone is an optimal choice for asymptomatic cases without subretinal fluid. 
When vision loss occurs, different treatment options include: photodynamic therapy 
(PDT), transpupillary thermotherapy, vascular endothelial growth factor (VEGF), laser 
photocoagulation, episcleral plaque radiotherapy, cryotherapy, external beam 
radiotherapy, and stereotactic radiotherapy [2]. Despite their efficacy, inducing tumor 
atrophy, all these treatments are associated with the potential risk of damaging the 
overlying retina. 
A new treatment has emerged for infantile hemangiomas: systemic propanolol [3]. 
Propanolol is a nonselective β-adrenergic receptor blocker commonly used for cardiologic 
indications. It seems to be safe and effective in orbital, eyelid and facial hemangiomas in 
children. 
Case Report 
A 59-year-old man with arterial hypertension (150/95 mm Hg) was seen in our department because 
of visual acuity (VA) decline and metamorphopsia of his left eye (OS) for 5 weeks. VA was 20/20 for his 
right eye and 20/200 for OS. A temporal superior CCH was evidenced in OS with foveal serous 
detachment (fig. 1). 
We performed laser photocoagulation (the patient refused treatment with PDT) and 3 months later 
VA improved to 20/100 but foveal serous detachment persisted (fig. 2). Thereafter we decided to begin 
treatment with oral propanolol daily (120 mg). One month later, VA improved to 20/20 and serous 
foveal detachment disappeared (fig. 3). In addition, his arterial hypertension was under control (125/80 
mm Hg). After 8 months of follow-up, both VA (20/20) and the macular thickness remained stable. 
Discussion 
Hemangiomas consist histologically of cavernous and capillary vascular networks. 
Their physiopathology is still poorly understood; nonetheless, VEGF and basic fibroblast 
growth factor (bFGF) have been involved in infantile hemangiomas growth [4]. Increased 
levels of these factors have been detected in cutaneous hemangiomas [5] and VEGF-
receptors have been evidenced in proliferative infantile hemangiomas [6]. 
In addition, it has been shown that hypoxia-induced factors important
 for postnatal 
vasculogenesis like hypoxia-inducible
 factor 1α (HIF-1α), HIF-2α and VEGF are
 up-
regulated in children with proliferative infantile hemangiomas, leading to VEGF 
expression by endothelial
 cells [4–7]. 
Propranolol is a nonselective β-adrenergic receptor blocker,
 and the adrenergic system 
is the major regulator of cardiac
 and vascular function. Capillary endothelial cells express 
β2-adrenergic
 receptors [7, 8] which modulate the release of nitric oxide,
 causing 
endothelium-dependent vasodilatation. In addition, β-adrenergic receptor
 stimulation  
Case Rep Ophthalmol 2011;2:84–90 
DOI: 10.1159/000325142 
Published online: 
February 25, 2011 






can induce modifications of signal transduction
 pathways of angiogenic factors such as 
VEGF or bFGF, enhancing neoangiogenesis in ischemic events [7–9]. Moreover, a study 
of the use of β-adrenergic
 receptor blockers for the treatment of cardiac hypertrophy 
revealed
 that carvedilol reversed levels of HIF-1α and VEGF to baseline values [10].  
Therefore propanolol may induce endothelium vasoconstriction, decrease expression 
of bFGF, HIF-1α and VEGF through the RAF–mitogen-activated protein kinase pathway 
[4, 8] and inhibit endothelial proliferation. Indeed, β-blockade induces apoptosis of 
cultured capillary endothelial cells [11]. 
Different treatments had been performed for this benign tumor. Laser 
photocoagulation induces resolution of subretinal fluid, exudative retinal detachment and 
tumor regression; however, subretinal fluid has a high tendency to recur, and 40% of 
patients require additional treatment [12]. Radiotherapy is effective in the majority of 
cases, but it is associated with significant treatment morbidity. Transpupillary therapy 
may avoid some of the limitations of laser photocoagulation (especially the failure to 
induce tumor regression) while avoiding complications of radiotherapy. PDT is the 
preferred treatment for subfoveal or juxtafoveal CCH. Verteporfin is an important vaso-
occlusive treatment, and PDT may destroy the tumor without damaging the overlying 
retina and its vascularization. If the tumor or subretinal fluid persist further, PDT re-
treatments can be performed, but repeated treatments and over-treatment or overlapping 
PDT spots may result in delayed choroidal atrophy and fibrosis, limiting the visual 
outcomes [2, 13]. Moreover, some authors suggest that it is preferable to avoid treatments 
within the fovea in order to decrease fibrosis and retinal pigment epithelium (RPE) 
changes [2]. 
Long-term visual prognosis for patients with CCH is guarded secondary to vision loss 
induced by subretinal fluid, macular edema, foveal distortion, and treatment side effects, 
like choroidal atrophy, fibrosis and RPE changes.  
Nowadays, eyelid and orbital infantile hemangiomas can be treated successfully with 
oral and topical β-blockers [14, 15]. This may entail a new treatment for refractory 
hemangiomas, foveal hemangiomas, or hemangiomas the treatment of which implies high 
risk of scarring or RPE changes, like tumors that need PDT retreatment or hemangiomas 
with thin retinal detachments. 
We hypothesized that this treatment would be useful in our patient, who showed no 
response to laser treatment, refused PDT, and presented poor VA. Although the 
treatment with β-blockers has been effective and safe in our patient, we are not able to 
determine whether laser treatment could have modified the final outcome. 
The good visual results after treatment with oral β-blockers may open a new treatment 
research line for CCH. Nevertheless, further studies and more cases are required to 
confirm our observation. 
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Fig. 1. Baseline appearance of the CCH: orange choroidal lesion with indistinct margins that blend with 
the surrounding choroid under the superior temporal arcade (a). Fluorescein angiography showing 
active leakage (b). Horizontal and vertical optical coherence tomography scans and retinal thickness 
map, showing serous macular detachment with foveal involvement (c). 
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Fig. 2. Fundus appearance 3 months after laser treatment: CCH remained unchanged with laser scars 
(a). Fluorescein angiography showing persistent active leakage (b). Horizontal and vertical optical 
coherence tomography scans and retinal thickness map, showing persistent foveal serous detachment 
(c). The central macular thickness measured 354 μm. 
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Fig. 3. Fundus appearance after 8 months of treatment with oral propanolol (a). Fluorescein 
angiography did not evidence active leakage (b). Horizontal and vertical optical coherence tomography 
scans and retinal thickness map, showing macular re-attachment with restitution of the photoreceptor 
layer integrity (c). The central macular thickness measured 280 μm. 
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